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Abstract
Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for 
which there is no targeted therapy1-3. BET bromodomain inhibitors, which have shown efficacy in 
several models of cancer4-6, have not been evaluated in TNBC. These inhibitors displace BET 
bromodomain proteins such as BRD4 from chromatin by competing with their acetyllysine 
recognition modules, leading to inhibition of oncogenic transcriptional programs7-9. Here we 
report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, 
establishing a rationale for clinical investigation and further motivation to understand mechanisms 
of resistance. In paired cell lines selected for acquired resistance to BET inhibition from 
previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug 
pump activation. BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports 
transcription and cell proliferation in a bromodomain-independent manner. Proteomic studies of 
resistant TNBC identify strong association with MED1 and hyper-phosphorylation of BRD4 
attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase. 
Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-
based combination strategies to anticipate clinical drug resistance.
To explore non-oncogene addiction to BRD4 in breast cancer, we studied a series of BET 
bromodomain inhibitors (BBI) across breast cell lines reflecting transcriptionally-defined 
breast cancer subtypes: luminal, HER2+, and TNBC2,10 as well as MCF10A and MCF12A 
basal/mesenchymal immortalized mammary epithelial cells (Supplementary Table 1). Potent 
inhibitory effects were observed preferentially in TNBC lines, compared to more resistant 
luminal lines (Fig. 1a). Analysis of potency of drug response and subtype or known driver 
mutations identified the basal subtype as the only significant association (p=0.0475) 
(Supplementary Table 1 and D.N.S.). BRD4 dependency was confirmed by RNAi and 
phenocopied BBI (Extended data Fig. 1a-c). JQ1 or BRD4 knock-down induced growth 
inhibition resulted in G1 arrest and apoptosis (Extended Data Fig. 1d-g). Expression of 
factors described to mediate JQ1 effect (MYC) or required for TNBC growth (JAK2/STAT3) 
showed no clear association with JQ1 sensitivity (Extended Data Fig. 1h and Extended Data 
Fig. 2a,b). JQ1 treatment of TNBC cells induced significant morphologic changes consistent 
with induction of senescence confirmed by β-galactosidase staining and luminal 
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differentiation evidenced by changes in the expression of basal and luminal markers 
(Extended Data Fig. 2c-d and Fig. 1b).
Extending the translational significance of these findings, we evaluated the ability of JQ1 to 
inhibit tumor growth in murine TNBC xenografts. Two week treatment efficiently inhibited 
established tumor growth from SUM159 and MDA-MB-231 lines, and patient-derived 
primary human TNBC xenografts (Fig. 1c and Extended Data Fig. 2e,f). Down-regulation of 
BRD4 using two independent TET-inducible shRNAs produced even more pronounced 
effects leading to complete tumor regression and failure to regrow even after discontinuing 
doxycycline treatment (Fig. 1c and Extended Data Fig. 2g). Evidence of BBI-induced basal-
to-luminal differentiation was confirmed in vivo (Extended Data Fig. 2f,h).
Using integrated epigenomic analysis (Supplementary Table 2), we identified the direct 
transcriptional targets of BBI in TNBC. BBI binding was identified at active promoter and 
enhancer regions using ChemSeq11 for biotinylated JQ1 (Bio-JQ1) enrichment and ChIP-seq 
for acetyl-histone (H3K27ac) and BRD4 enrichment, with the three marks showing near 
perfect co-localization (Fig. 1d and Extended Data Fig. 3a). BBI efficiently displaced 
chromatin-bound BRD4 in treated SUM159 (Fig. 1e and Extended Data Fig. 3b) and in 
SUM149 cells (Extended Data Fig. 3c). To identify biologically relevant, direct targets of 
BBI in SUM159 and SUM149 cells, we quantified binding of Bio-JQ1 and BRD4 genome-
wide and found strong enrichment at 219 and 159 super-enhancers, respectively (SEs; Fig. 
1f and Extended Data Fig. 3d and Supplementary Table 3)8,9,12,13. TFs with known roles in 
breast cancer, such as POU5F1B/MYC14 and HIF1α15, were evident among top SE-
associated genes in both lines. Kinetic effects of JQ1 treatment on gene expression 
demonstrated preferential SE-associated gene down-regulation (Fig. 1g and Extended Data 
Fig. 3e,f). Expression changes were observed within 3 hours after JQ1 treatment and, as 
expected, more genes were significantly down- than up-regulated (Extended Data Fig. 3g-j, 
and Supplementary Table 4). Unsupervised Metacore16 analysis of JQ1 affected target 
pathways revealed down-regulation of regulatory and effector genes in anti-apoptotic and 
JAK/STAT signaling pathways (Extended Data Fig. 3k). These data support selective 
disruption of SE-associated genes by JQ1, leading to deregulation of coordinated 
transcriptional pathways involved in cell proliferation, invasion, and survival.
Dissecting resistance to targeted therapy is critical to elucidate mechanisms of drug and 
target action, and to suggest approaches to treat or anticipate drug resistance in patients. 
Therefore, we established BBI-resistant TNBC cell lines by long-term culture of both 
SUM159 and SUM149 cells in escalating JQ1 doses. Low (0.5 μM) and high (2.0 μM) doses 
of JQ1 severely impaired proliferation of parental SUM159 and SUM149 lines, reducing 
viable cells after 6 days (Fig. 2a and Extended Data Fig. 3l). In contrast, JQ1-resistant cells 
(SUM159R and SUM149R) proliferated linearly, even in high JQ1 doses (20 μM) (Fig. 2a 
and Extended Data Fig. 3l). BBI-resistance is not attributable to drug export, as MDR1 and 
other transporters are not transcriptionally up-regulated (Extended Fig. 4a), co-incubation 
with MDR1 inhibitors (verapamil) had no effect (Extended Data Fig. 4b), and structurally 
divergent BBIs are equally inactive as JQ1 (Fig. 2b). Further support is provided by the 
equivalent chromatin engagement of BRD4 in sensitive and resistant cells, demonstrated by 
ChemSeq with Bio-JQ1 (Extended Data Fig. 4c). Notably, BBI-resistant TNBC cells retain 
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sensitivity to compounds from orthogonal active drug classes, such as CXCR2 and JAK2 
inhibitors17; establishing specific resistance to BBIs (Extended Data Fig. 4d). Adaptive drug 
resistance was not attributable to outgrowth of a minor subpopulation of pre-existing 
resistant cells, as 10 independent single cell-derived clones showed similar resistance 
profiles to pooled SUM159R cells (Extended Data Fig. 4e). Similar results were obtained in 
vivo, as SUM159R derived xenografts derived were JQ1 unresponsive (Extended Data Fig. 
4f). In all resistant TNBC populations studied, exome sequencing failed to identify 
alterations in BET bromodomain-encoding genes (e.g., gatekeepers) or known driver genes 
(parallel pathway activation; Supplementary Table 5).
Absent new genetic alterations, we explored the plausibility of an epigenomic mechanism of 
resistance. Differential enhancer analysis revealed a significant gain of SEs in resistant 
SUM159R cells (ChemSeq; Fig. 2c and Supplementary Table 6). The gain of Bio-JQ1 SEs 
was associated with enrichment for BRD4 binding to these genomic loci (Fig. 2d) and 
increased transcription of associated genes (Fig. 2e). An upstream/intragenic region of 
H3k27ac at the BCL-xL locus featured prominently among top gained SEs in SUM159R 
(Fig. 2f), consistent with increased BCL-xL mRNA and protein expression in resistant cells 
(Supplementary Table 7, Extended Data Fig. 4g). Functionally, cells with acquired resistance 
to BBI featured a concordant switch in JQ1 anti-apoptotic response based on dynamic BH3 
profiling18,19 (Extended Data Fig. 4h).
Observing emergent enhancers in resistant cells, we assessed whether BBI-resistant TNBC 
cells retained non-oncogene addiction to BRD4. Notably, we observed loss of SUM159R 
cell viability upon BRD4 knockdown (Extended Data Fig. 5,b). Together these studies 
establish persistence of BRD4 addiction despite resistance to bromodomain inhibition, 
establishing the plausibility of bromodomain-independent recruitment of BRD4 to enhancers 
in BBI-resistant TNBCs. To test this hypothesis, we performed BRD4 ChIP-seq on sensitive 
and resistant cells with and without JQ1. JQ1 neither displaced BRD4 from chromatin in 
SUM159R (Fig. 2g), nor meaningfully influence epigenome structure by H3K27ac ChIP-seq 
(Extended Data Fig. 5c-g). Notably, several luminal markers (FOXA1, CD24, and luminal 
cytokeratins) were elevated in SUM159R cells in cell culture and in vivo (Extended Data 
Fig. 5h,i), supporting a model whereby resistance arises via essential BRD4 recruitment to 
chromatin in a bromodomain-independent manner. Similar observations were made in 
SUM149R cells and in TNBC cells inherently resistant to JQ1 (Extended Data Fig. 3h-j; 
Extended Data Fig. 6a-d), suggesting a general mechanism of epigenomic resistance to BBI.
To disclose potential differences in BRD4-associated complexes between sensitive and 
resistant SUM159 cells, we performed quantitative proteomics using RIME (rapid 
immunoprecipitation mass spectrometry of endogenous proteins)20 with and without JQ1. 
Analysis of BRD4-associated proteins identified relative enrichment of MED1 and BRD3 in 
JQ1-treated resistant cells (Fig. 3a, Extended Data Fig. 7, and Supplementary Table 8). 
BRD4 immunoprecipitation followed by immunoblot for MED1 and BRD3 revealed that 
JQ1 efficiently displaced BRD4 from MED1 in sensitive cells, but not in resistant cells (Fig. 
3b), a result confirmed in SUM149 and BBI-resistant SUM149R, as well as inherently 
resistant TNBC and luminal lines (Extended Data Fig. 8a). Though elevated BRD3 
abundance was observed in SUM159R, increased association of BRD4 and BRD3 was not 
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confirmed by immunoblot, (Fig. 3b). To assess functionally whether increased recruitment 
of BRD4 to chromatin by MED1 underlies resistance to JQ1, we expressed an exogenous 
bromodomain-inactivated mutant (BDmut) with concomitant knock-down of endogenous 
BRD4 (Extended Data Fig. 8b,c). Downregulation of endogenous BRD4 decreased cell 
growth both in parental and resistant cells, which was rescued by enforced expression of 
wild type BRD4 (Fig. 3c). BDmut BRD4 expression failed to rescue parental SUM159 cells, 
but supported growth of JQ1-resistant SUM159R consistent with an evident bromodomain-
independent mechanism of BRD4 recruitment (Fig. 3c). Next, we assessed the sensitivity of 
cells expressing BDmut BRD4 to JQ1, observing increased sensitivity to JQ1 In parental 
SUM159 cells exogenously expressing BDmut (Fig. 3d). In contrast, expression of BDmut 
BRD4 in SUM159R cells rescued the anti-proliferative effect of JQ1 (Fig. 3e), although this 
could partially be due to the slower growth of BDmut expressing cells. Together, these 
studies suggest BBI-resistance is associated with increased binding of BRD4 to MED1, in a 
bromodomain-independent manner unaffected by JQ1.
A recent study reported that the stability and nuclear localization of BRD4 is increased with 
phosphorylation by casein kinase II (CK2)21. To explore the contribution of BRD4 
phosphorylation to BBI-resistance, we performed immunoblot analysis in parental and 
resistant cells and found a marked increase of phospho-BRD4 (pBRD4) in resistant cells 
(Fig. 4a and Extended Data Fig. 8d). Small-molecule inhibition of CK2 decreased BRD4 
phosphorylation in SUM159 and SUM159R cells (Extended Data Fig. 8e). These results 
imply BRD4 hyperphosphorylation in resistant cells either due to increased phosphorylation 
by CK2 or, alternatively, to decreased dephosphorylation by an as yet unidentified BRD4 
phosphatase. We therefore first analyzed CK2 activity in parental and resistant cells by 
performing pan-CK2 substrate immunoblots and detected no significant differences in CK2 
activity (Extended Data Fig. 8f).
Inactivation of the PP2A phosphatase tumor suppressor gene occurs commonly in breast 
cancer and is associated with therapy resistance22; PP2A also often opposes CK2 
function23,24. Thus, we investigated whether PP2A may dephosphorylate BRD4 and whether 
decreased PP2A activity could lead to BBI-resistance. Downregulation of PP2A catalytic 
subunit (PP2CA) in SUM149 and SUM159 cells led to increased BRD4 phosphorylation, 
establishing PP2A as a previously unrecognized BRD4 phosphatase (Fig. 4b), further 
supported by pharmacologic inhibitors of PP2A that showed similar effects (Extended Data 
Fig. 8g). To strengthen the link between PP2A activity and BBI-resistance, we tested the 
JQ1 sensitivity of SUM149 cells following the knock-down of PP2A C subunit and 
determined that downregulation of PP2A decreased JQ1 sensitivity (Fig. 4c). We have 
collaboratively reported phenothiazine compounds as activators of PP2A enzymatic 
activity25. Thus, we analyzed pBRD4 levels in SUM159R, SUM149R, and other cell lines 
after short-term treatment with phenothiazine (PTZ) and detected rapid dephosphorylation 
of BRD4 (Fig. 4d and Extended Data Fig. 8h). Combined treatment with PTZ and JQ1 
overcame BBI-resistance in SUM159R cells (Fig. 4e). To investigate the functional role of 
BRD4 hyperphosphorylation in BBI-resistance, we analyzed whether BRD4 
phosphorylation influences MED1 binding. Indeed, SUM159R cells treated with CK2 
inhibitor or PTZ both lead to decreased MED1 abundance in BRD4 immunoprecipitations, 
suggesting that pBRD4 binds MED1 more efficiently than BRD4 (Fig. 4f,g).
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To functionally assess the role for BRD4 phosphorylation in BBI-resistance and MED1 
binding, we generated BRD4 constructs encoding mutants that cannot be phosphorylated by 
CK2 (7 serine to alanine substitutions; “7A mutant”) or mimic constitutive phosphorylation 
(7 serine to aspartate substitutions; “7D mutant”). We first assessed the ability of these 
constructs to rescue effects of endogenous BRD4 knock-down in stable cell lines (Extended 
Data Fig. 8b,c). We observed expression of both 7D and 7A mutants supporting the growth 
of both parental SUM159 and JQ1-resistant SUM159R cells (Fig. 3d). Next, we analyzed 
MED1 binding and subcellular localization of 7A and 7D mutants +/− JQ1. We found that 
the 7A mutant displays weaker MED1 binding compared to WT BRD4 and completely 
dissociates after JQ1 whereas the 7D mutant seems to have higher affinity for MED1 that 
unaffected by JQ1 treatment (Fig. 4h and Extended Fig. 8i). Lastly, we assessed the 
sensitivity of cells expressing 7A or 7D mutant BRD4 to JQ1. In parental SUM159 cells 
exogenously expressed 7D mutant BRD4 decreased sensitivity to JQ1 whereas the 7A 
mutant slightly increased sensitivity (Fig. 4i). In contrast, expression of 7A mutant BRD4 in 
SUM159R cells restored JQ1 sensitivity whereas the 7D mutant showed a modest decrease. 
These results strongly support the hypothesis that hyperphosphorylation of BRD4 arises 
from decreased PP2A activity in BBI resistant cells leading to increased binding of BRD4 to 
MED1, recruitment to chromatin and decreased responsiveness to bromodomain inhibition.
To explore the clinical relevance of phospho-BRD4 (pBRD4) in BET inhibitor-naive TNBC, 
we performed immunofluorescence analysis of a tissue microarray (TMA) featuring of 89 
patient-derived TNBC specimens. First, we validated the pBRD4 immunofluorescence assay 
by comparing xenografts derived from SUM159 and SUM159R cell lines and detected 
significantly higher pBRD4 in SUM159R cells (Extended Data Fig. 9a). We detected strong 
pBRD4 staining among a subset of TNBCs (Extended Data Fig. 9b,c), and variable staining 
overall that was not correlated with expression of the androgen receptor (AR) and basal 
cytokeratins (bCK; Extended Fig. 9d,e) and it was not significantly associated with disease 
outcomes (Supplementary Table 9 and Extended Data Fig. 9f).
To extend the translational relevance of our findings, we conducted synergy studies of JQ1 
with molecules targeting BCL-xL (ABT737), a gained super-enhancer in SUM159R cells, 
and modulators of BRD4 phosphorylation, the CK2 inhibitor CX-4945 and the PP2A 
activator perphenazine (PPZ). We observed significant synergy between JQ1 and all three 
compounds studied (Extended Data Fig. 10), establishing a rationale for combination studies 
of BBI in TNBC to improve response and to anticipate BBI resistance.
BRD4 inhibition has demonstrated efficacy in disparate models of cancer in a rapidly 
expanding literature. Despite apparent resistance in the vast majority of tumor types, as we 
observed here in TNBC, mechanisms of BBI-resistance have not been mechanistically 
explained. As this research was in review, two studies reported moderate emergent resistance 
to BBI in murine AML associated phenotypically with a stem-like state and WNT pathway 
activation26,27. Interestingly, in our study TNBCs with more basal/stem cell-like features and 
WNT pathway activation are more sensitive to BET inhibition, whereas resistant disease 
emerges as epigenomic adaptation to a more differentiated luminal phenotype. Our findings 
of persistent BET bromodomain dependency despite BBI-resistance, as well as pBRD4 
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staining in resistant disease should be studied in these murine AML models and further in 
human leukemia.
Integrating approaches in epigenomics, proteomics, and chemical biology, we provide an 
example of epigenomic drug resistance by an epigenetic mechanism, where in BBI resistant 
cells, decreased PP2A activity leads to hyperphosphorylated BRD4, which binds more 
strongly to MED1, facilitating a bromodomain-independent chromatin recruitment 
mechanism. This research proposes putative combination strategies to anticipate and 
overcome BBI resistance, including pairing with BCL-xL inhibitors (e.g., ABT-737) or CK2 
inhibitors, and guides the development of second-generation BBIs that disrupt BET function 
via orthogonal biophysical or biochemical actions. More immediately, the robust efficacy 
observed in pre-clinical models supports the development of BET inhibition in TNBC alone, 
and in combination with mechanism-based targeted therapies.
METHODS
Cell lines and breast tumor tissues
Breast cell lines were obtained from the ATCC and Dr. Steve Ethier, University of Michigan, 
Ann Arbor, MI (SUM series). Cells were cultured in media recommended by the provider, 
their identity was confirmed by STR analysis, and they were regularly tested for 
mycoplasma. Breast tumor samples were collected using protocols approved by the DF/HCC 
Institutional Review Board, informed consent was obtained from all patients. Tumors were 
minced with razor blades and digested with stirring for 3-4 hours at 37°C in DMEM/F12 
with 2 mg/mL BSA, 2 mg/mL collagenase type IV, and 2 mg/mL hyaluronidase. After 
digestion, cells were filtered through 500-micron mesh, washed in DMEM/F12 with 5% 
FBS, frozen in DMEM/F12 with 5% FBS and 10% DMSO, and stored in liquid nitrogen for 
subsequent xenograft studies. PDX IDC50 was derived from a primary tumor of highly 
invasive metaplastic TNBC resistant chemo and radiation therapy leading to the rapid death 
of the patient. Exome sequencing of the tumor and xenograft identified numerous mutations 
including heterozygous frameshift mutation in PTEN (chr10_89701964-89701964_A) and 
CDH1 chr16_67400242-67400242_C). PDX EL-12-58 was derived from a liver metastasis 
of a heavily pretreated basal-like TNBC, Oncopanel mutation testing identified homozygous 
mutations in BRCA2 (p.S1970*), TP53 (p.I232fs), TSC2, FLT3, and ROS1, and lower 
frequency mutations in RAD21, JAK3, ARID1B, ARID1A, KDM6A.
High-Throughput Screening of BET Bromodomain Inhibitors in breast cell line panel
We tested a panel of compounds (synthesized in the Bradner lab) in 40 human breast cell 
lines in a 384-well format at 2,000 cells per well using a semi-automated screen essentially 
as described5. Cell viability at 72 hr was evaluated using ATPlite (Perkin Elmer).
Synergy Studies
SUM149, SUM149R, SUM159, and SUM159R cells were seeded in sterile, white, opaque 
384-well microtiter plates (Thermo), using an automated dispensing system (BioTek 
EL406), at 1,000 cells per well in 50 μl of media. Drugs were delivered in DMSO by robotic 
pin transfer with a JANUS workstation (100 nl) to achieve a matrix of pairwise dose-
Shu et al. Page 7
Nature. Author manuscript; available in PMC 2016 July 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
response incubations of each compound, each pair having eight replicates. Following 72 
hours of incubation, ATP levels were determined for treated cells and vehicle controls 
(ATPlite, PerkinElmer). Data were normalized to vehicle controls. Combination indices 
were determined using the median-effect principle of Chou and Talalay28 (CalcuSyn 
Software). Isobologram plots were generated with GraphPad Prism software. Points 
represent paired values of drug concentrations assessed for synergism. The diagonal line 
signifies drug additivity. Points above the line represent antagonistic drug combinations, and 
those below the line represent synergistic drug combinations. Synergy assays were 
performed in triplicates and repeated 2-3 times.
Xenograft assays
For xenograft assays 5-6-weeks old female CrTac:NCr-Foxn1nu and NOD.Cg-Prkdcscid 
Il2rgtm1Sug/JicTac mice were purchased from Taconic. Tumors were induced by bilateral 
orthotopic mammary fat pad injection of 1×106 cells in 50% Matrigel (BD Biosciences) in 
DMEM/F12 or Medium 171 (except for IDC50-X cells, which were injected with 3% FBS 
and 4 mg/ml collagen gel in Medium 171). Animal experiments were conducted following 
protocol 11-023 approved by the Dana-Farber Cancer Institute Animal Care and Use 
Committee. For all the xenograft studies, the sample size of each group (5-10 mice) is 
indicated in the figures. We performed pilot experiments using a few (5-10) mice/group 
followed by larger studies if needed to reach statistical significance and repeated 
experiments to ensure reproducibility. Due to the nature of the performed experiments, no 
randomization and no blinding was used as it was deemed unfeasible. However, the resulting 
tumors were analyzed in a blinded manner. Mice were administered JQ1 (50mg/kg, daily), 
vehicle only (control) for 14 days beginning at day 14 (SUM159), or doxycycline at day 21 
(SUM159-shBRD4) after injection. Mice were euthanized and tumors evaluated 28 and 60 
days after injection of parental and TET-inducible shBRD4-expressing SUM159 cells into 
mammary fat pads.
Cellular viability, senescence, MDR, and BH3 profiling assays
Cell viability and growth assays (Fig. 1a, Fig. 2a,b, Fig. 3d,e, Fig. 4c,i, Extended Fig. 1a,b, 
Extended Fig. 3i, Extended Fig. 4d,e,g,h, Extended Fig. 10), cycle, apoptosis, and MDR 
assays were performed in triplicates and repeated 2-3 times. For cell proliferation assays, 
cells were plated at 500 cells per well in 96-well plates and treated the next day with 
inhibitors, DMSO or doxycycline (500ng). Cells were cultured at 37°C with 5% CO2 in the 
media described-above, and cell viability was measured using CellTiter-Glo three days after 
treatments. For cell growth assays, cells were plated at 5000 (SUM159) or 20000 (SUM149) 
cells per well in 6-well plates and treated the next day with inhibitors. Cells were counted 
every three days by cell counter. Cellular apoptosis was analyzed with an APC AnnexinV/
7ADD Apoptosis Detection kit (BD Pharmingen). AnnexinV/7AAD assessments and cell 
cycle graphics were generated using FlowJo software V7.6.1 for Windows (Tree Star). 
Senescence Beta-gal staining was performed using Senescence β-Galactosidase staining kit 
from Cell signaling. Briefly, after JQ1 treatment (500nM) for 72h, SUM159 and MDA-
MB-231 cells were fixed by Fixative Solution for 15 min, followed by β-Galactosidase 
solution incubation overnight at 37 °C. The staining was checked under microscope for the 
development of blue color. Multi-Drug Resistance Assay was performed with MDR assay 
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kit from Cayman Chemical (600370). Briefly, SUM159 and SUM159R cells were treated 
with JQ1 or DMSO for 30 min in SUM medium. Verapamil was used as a positive control at 
1:1000 dilution. Calcein AM/Hoechst Dye staining solution was added after that and cells 
were incubated at 37 °C for 15 min. The cells were analyzed by fluorescent microscope and 
FACS. Cell cycle analysis was performed 72 hr after JQ1 treatment or BRD4 
downregulation with doxycycline using propidium iodide (PI) staining. Cells were 
resuspended in 1 ml of growth medium supplemented with 2 μg/ml PI (Life Technologies) 
as final concentration. After 60 min at 37°C in the dark, analysis was performed on a FACS 
AriaII cytometer (BD Biosciences). The cell cycle was plotted as histogram after excluding 
doublets. Cell synchronization Procedure. SUM159 cells were treated with nocodazole 
(200ng/ml) for 12h and then cells were tapped to detach from the plates. After washing 
twice with PBS, cells were replated with or without JQ1 in collagen coated plates. Cells 
were collected at 0, 3, 6, 12 h time point for FACS and immunoblot analysis. Dynamic BH3 
profiling was performed using the JC-1 plate method as previously described18,19. Briefly, 
2.5×105 cells were seeded in T25 flasks in the presence of 500 nM or 5 μM JQ1 for 72 or 96 
hours. Cells were trypsinized, suspended in MEB (150 mM mannitol, 10 mM HEPES, 50 
mM KCl, 5 mM succinate, 20 μM EGTA, 20 μM EGTA, 0.1% protease-free BSA, pH 7.5 +/
− 0.1), and 1-2×104 cells were added in 15 μL of MEB to each well of a 384 well Fluotrac 
200 plate containing 15 μL/well of either peptides at 2X final concentration, buffer only, or 
50 μM alamethicin in MEB supplemented with 2μ JC-1, 10 mM 2-mercaptoethanol, 20 
μg/mL oligomycin, and 50 μg/mL digitonin. Fluorescence at Em 590 +/− nm and Ex 545 +/
− 10 nm was recorded at 5 min intervals at 32°C. The area under each curve was normalized 
to the alamethicin and buffer controls as:
% Depolarization = 1- [(AUC sample – AUC alamethicin) / (AUC buffer – AUC alamethicin)]. 
Delta priming was calculated per peptide treatment as: Delta Priming = (Depolarization 
Treated) – (Depolarization Untreated). Positive delta priming indicates an increase in 
priming due to treatment and an increased potential for apoptosis at later time points.
Immunofluorescence staining and image and statistical analysis of tissue microarrays
Antibodies used for immunofluorescence were CK18 (Dako, M7010), CK17 (Dako, 
M7046), HMW CK (Dako, M0630), LMW CK (Dako, M0631), CD44 (NeoMarkers, 
MS-668-P1), CD24 (NeoMarkers, MS-1279-P1), p-STAT3 (Cell Signaling, 9145S), VIM 
(Dako, M073501), CDH1 (BD Biosciences, 610181), FLAG (Sigma, F1804), BrdU (Roche, 
11170376001), pBRD4 (a gift from Dr. Chiang at University of Texas Southwestern Medical 
Center), and AR (Cell Signaling, 5153S). Immunofluorescence experiments were performed 
in cultured cells or in whole sections of formalin-fixed paraffin embedded (FFPE) xenograft 
tumors. The staining was performed as described29. Antibody dilutions were as follows: p-
STAT3 (1:25), CD44 (1:100), CD24 (1:100), CK18 (1:200), CK17 (1:200), HMW CK 
(1:100), LMW CK (1:100), VIM (1:100), CDH1 (1:100), FLAG (1:50), BrdU (1:200), 
pBRD4 (1:200), and AR (1:50). The Dana-Farber Breast Cancer Tissue Microarray (TMA) 
consists of primary TNBC samples from approximately 83 patients who underwent 
definitive breast surgery at Brigham and Women's Hospital between 1/1/1997 to 12/31/2005. 
Formalin-fixed, paraffin-embedded breast cancers were collected from the archives of the 
Department of Pathology at Brigham and Women's Hospital. Best blocks and best areas for 
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coring were identified and selected by a breast pathologist (DD) to represent different area 
of the tumor. Results of immunohistochemical studies for estrogen (ER) and progesterone 
receptor (PR) and HER2 and FISH assay results for HER2 were extracted from pathology 
reports. TMA construction was carried out in the Dana-Farber/Harvard Cancer Center Tissue 
Microarray Core Facility. Three 0.6 mm cores were taken from different marked areas in 
each case and placed into a recipient block using a manual arrayer (Beecher Instruments). 
Specimens are arrayed in triplicate. Participants signed consent for research use of tissue and 
the linking of tumor specimens to clinical follow-up. Clinical data on these patients was 
collected retrospectively at first presentation, at 4, 9, 18, 30, and 42 months, and annually 
thereafter. After 9.3 years median follow up, 24 recurrences and 14 deaths have been 
recorded. The data elements are the following: staging, tumor pathology, diagnostic and 
follow-up tests performed, treatments administered (surgery, radiation and systemic 
therapy), and recurrence. Although the patients in this cohort were not treated as part of a 
clinical trial protocol, they were treated relatively uniformly as per Dana-Farber clinical 
practice guidelines. This serves to minimize confounding due to treatment heterogeneity. 
The TMA was stained with pBRD4 (1:200) antibody and imaged manually on Yokagawa 
spinning disc confocal microscope. Three images were taken per each core for 240 out of 
267 cores, for the remaining 27 one or two images were taken due to tissue loss or low 
tumor content. Image analysis was performed with ImageJ software macro (code available 
upon request). Phospho-BRD4 staining mean intensity was calculated per individual nucleus 
within an image. The mean intensity per image was normalized to nuclei count. For clinical 
outcome analysis patients were dichotomized as ‘High’/’Low’ pBRD4 by median intensity 
(Supplementary Table 9). Disease outcomes were evaluated in 83 of 89 TMA samples (3 
were not TNBC by definitive pathology, 2 did not have clinical data available, one was a 
repeat biopsy on a patient). Recurrence-free survival (RFS) was defined as the interval from 
the date of initial surgical resection to the date of recurrence (local or distant), or date of last 
known contact if the patient was alive and has not recurred. RFS and overall survival were 
estimated using the Kaplan-Meier product-limit method, with hazard ratios and 95% 
confidence intervals from a univariate Cox proportional hazard model.
siRNAs and lentiviral shRNA and expression constructs
For siRNA transfection cells were plated at 2,000 cells per well in 96-well plates and 
cultured at 37°C with 5% CO2 in the media. The next day, cells were transfected in triplicate 
with siGENOME SMARTpools for the genes of interest or “Non-Targeting siRNA” controls 
using DharmaFECT 1 (Dharmacon). The sequences of the siRNAs in the SMARTpools are 
listed in Supplementary Table 10. Cell viability was measured using CellTiter-Glo 
(Promega) three days after transfections, with the effects of each siRNAs treatment on each 
cell line compared to the effects of no siRNAs.
TET-inducible pLKO-TET-ON lentiviral constructs were packaged by co-transfection of the 
lentiviral hairpin containing plasmid PLKO.1 and the helper plasmids pCMV-dR8.91 and 
pMD2.G-VS.V-G into HEK293T cells using Lipofectamin (Life Technolgies). Following 
transduction via spinoculation for 30 min hr at 1000 g and selection with 1 μg/ml puromycin 
for 72 hr (Sigma, St. Louis, MO), knockdown efficacy was determined by western blotting 
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and cells were seeded for proliferation assays as described above. Sequences of shRNAs 
used are listed in Supplementary Table 10.
Full length BRD4 in pCDNA3 was a gift from Dr. French at Brigham and Women's 
Hospital, Harvard Medical School. Mutations of BRD4 BD1 (N140A) and BD2 (N433A) 
bromodomains, 7A and 7D mutants were generated using a Quickchange Multi Site-
Directed Mutagenesis Kit (Agilent Technologies) using primers listed in Supplementary 
Table 10 and subsequently verified by sequencing.
Immunoblotting and immunoprecipitation experiments
Cells were lysed five days after transfection with siRNAs in RIPA buffer. Proteins were 
resolved in SDS-polyacrylamide gels (4%–12%) and transferred to PVDF membranes by 
using a Tris-glycine buffer system. Membranes were blocked with 5%milk powder in 0.1% 
Tween20 in PBS (PBS-T) for 1 hr at room temperature followed by incubation with primary 
antibodies at 1:1000 dilution in 2.5% milk PBS-T. For immunoprecipitation, nuclear extracts 
were prepared as follow: 10× 106cells were resupended in 5ml Buffer A: 10mM Tris pH 7.9, 
1.5mM MgCl2, 10mM KCl, 0.05% NP-40, 1mM DTT, and protease and phosphatase 
inhibitors. Cells were incubated on ice for 15 min and gently vortexed every 5 min. After 
centrifugation at 2,000g for 5 min, pellets were suspended in 0.3 ml buffer B (20mM Tris 
pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5mM MgCl2, 1mM KCl, 0.5% NP40, 0.2mM EDTA, 
1mM DTT, and protease and phosphatase inhibitors) and incubated for 5 min on ice. After 
centrifugation of the lysates at 14g for 10 min at 4°C, supernatant was diluted with 0.6 ml 
buffer A, and added NP-40 to final 0.5% and treated with DNase I. The samples were then 
incubated at 4°C overnight with BRD4 or Flag antibodies at 1:100 dilution and 
immunoprecipitates were collected on Dynabeads Protein G for 2 hr. Beads were washed 
with buffer B containing 150mM NaCl and 0.5% NP-40 three times and then resuspended in 
gel loading buffer. Immunoblotting and immunoprecipitation experiments were repeated 2-3 
times.
Antibodies and Inhibitors
Antibodies used for immunoblotting, immunoprecipitation and ChIp-seq were as follows: 
BRD4 (Bethyl, A301-985A), MED1 (Bethyl, A300-793a), BRD3 (Bethyl, A302-368A), 
BRD2 (Bethyl, A302-583A), MYC (Santa Cruz, sc764), p-STAT3 (Cell Signaling, 9145S), 
STAT3 (Cell Signaling, 4904), p-STAT5 (Cell Signaling, 9351), p-JAK2 (Cell Signaling, 
3771), CYCLIN D1 (Cell Signaling, 2922), p-H3 (Cell Signaling, 12201), CK2 substrate 
(Cell signaling, 8738), PP2A-A (Cell signaling, 2039), PP2A-C (Cell signaling, 2038) and 
p-BRD4 was a gift from Dr. Chiang at University of Texas Southwestern Medical Center. 
Antibodies used for ChIP-seq were BRD4 (Bethyl) Histone H3K27ac (Abcam, ab4729). 
CXCR2 inhibitor (239819) and CK2 inhibitor (218860) were from CalBiochem, JAK2 
inhibitor (INC424), MEK inhibitor (GSK1120212, S2673) and PI3K inhibitor (BKM120, 
S2247) were from Selleckchem, Phenothiazine (1525707) and perphenazine (1511000) was 
from Sigma, ABT-737 (s1002) was from Selleckchem. Inhibitor treatment for immunoblot 
analyses was conducted for 3 hrs.
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SILAC-RIME Experiments and data analysis
SUM159 and SUM159R cells were grown in R/K-deficient SILAC DMEM (paa; E15-086), 
10% dialyzed serum (Sigma-Aldrich; F0392), and supplemented with 800 μM L-
Lysine 13C615N2Hydrochloride and 482 μM L-Arginine13C615N4 hydrochloride (Cambridge 
Isotope lab) for “heavy”-labeled media or 800 μM L-Lysine 12C614N2-Hydrochloride and 
482 μM L-Arginine 12C614N4 hydrochloride for “light”-labeled media. After SILAC 
labeling, RIME was performed as described20. Word clouds for Fig. 5a were generated using 
R version 3.1.0 and the R package “wordcloud” version 2.5. The size of the tag reflects the 
square root of the MASCOT score of the protein (the choice of square root is arbitrary, but 
visually appealing). Experiments were filtered against the Contaminant Repository for 
Affinity Purification Mass Spectrometry Data30, considering any protein which occurs in at 
least 20 negative control experiments to be contamination, hence removed from the data set. 
Refseq protein IDs provided by the contaminant repository were converted to Uniprot IDs 
found in the mass spec experiments using mappings from the Bioconductor package 
“org.Hs.eg.db”, version 2.14 (Carlson M. org.Hs.eg.db: Genome wide annotation for 
Human. R package version 3.0.0). SILAC RIME experiments were performed in duplicates 
and repeated 2-3 times.
In vitro Chem-seq, ChIP-seq, and RNA-seq
Chem-seq was performed essentially as described11. ChIP-seq: SUM159 and SUM159R 
cells (4×107) were grown in SUM Medium. The media were then removed and replaced 
with media containing 1% formaldehyde (EM grade; tebu-bio) and crosslinked for 8 min. 
Crosslinking was quenched by adding glycine to a final concentration of 0.2 M. The cells 
were washed with ice-cold PBS, harvested in PBS, and the cell pellet was washed with PBS. 
The nuclear fraction was extracted by first resuspending the pellet in 10 ml of LB1 buffer 
(50mM HEPES-KOH [pH 7.5], 140mMNaCl, 1mMEDTA, 10% glycerol, 0.5% NP-40 or 
Igepal CA-630, and 0.25% Triton X-100) for 10 min at 4°C. Cells were pelleted, 
resuspended in 10 ml of LB2 buffer (10 mM Tris-HCL [pH 8.0], 200 mM NaCl, 1 mM 
EDTA, and 0.5 mM EGTA), and mixed for 5 min. Cells were pelleted and resuspended in 
300 μl of LB3 buffer (10 mM Tris-HCl [pH 8], 100 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 0.1% Na-deoxycholate, and 0.5% N-lauroylsarcosine) and sonicated in a covaris 
sonicator for 10 min. A total of 30 μl of 10% Triton X-100 was added, and lysate was 
centrifuged for 10 min at 20,000 rcf to purify the debris. The supernatant was then incubated 
with 100 μl of magnetic beads (Life Technologies) prebound with 20 μg BRD4 antibody 
(Bethyl, A301-985A), and immunoprecipitation (IP) was conducted overnight in the cold 
room. The beads were washed ten times in 1 ml of RIPA buffer and twice in 100mM 
ammonium hydrogen carbonate (AMBIC) solution. DNA was eluted in elution buffer (50 
mM Tris-HCl pH 8, 10 mM EDTA, and 1% SDS). Cross-links were reversed overnight at 
65°C. RNA and protein were digested with 0.2 mg/mL RNase A for 2 hr followed by 0.2 
mg/mL Proteinase K for 1 hr. DNA was purified with phenol chloroform extraction and 
ethanol precipitation. Libraries for Illumina sequencing were prepared following the 
Rubicon ThruPLEX-FD kit for 10-12 cycles.
RNA-seq: SUM159 and SUM159R were incubated in biological duplicates for 3, 12 and 24 
hr with 500 nM of JQ1 or DMSO treatment. Total RNA was extracted using the standard 
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QIAGEN RNeasy kit (74106). RNA concentrations were measured and quality controlled on 
a Bioanalyzer, RNA-Seq libraries were made using Illumina True-Seq RNA kits using the 
Sciclone NGSx workstation.
All RNA-seq and ChIP-seq experiments were performed in duplicates.
Genomic data analyses
Accessing data generated in this manuscript—All ChIP-seq, Chem-seq, and RNA-
seq data generated in this publication can be found online associated with GEO Publication 
Reference ID GSE63584 (www.ncbi.nlm.nih.gov/geo/). Supplementary Table 2 lists all 
sequencing datasets and their corresponding GEO GSM accession IDs.
Gene sets and annotations—All analysis was performed using RefSeq (NCBI37/
HG19) human gene annotations.
RNA-seq data processing and gene expression quantification—All RNA-Seq 
datasets were aligned to the transcriptome using Tophat231 (version 2.0.11) using the 
Illumina igenomes NCBI37/HG19 UCSC transcriptome build retrieved from http://
ccb.jhu.edu/software/tophat/igenomes.shtml. Alignments were performed using default 
parameters. Transcript expression quantification was performed using Cufflinks32 (version 
2.2.0) with default parameters to generate gene expression values in units of FPKM.
ChIP-seq and Chem-seq data processing—All ChIP-seq and Chem-seq datasets 
were aligned using Bowtie233 (version 2.2.1) to build version NCBI37/HG19 of the human 
genome or build version NCB37/MM9 of the mouse genome. Alignments were performed 
using the following criteria: -k 1, with all other parameters set to default. These criteria 
preserved only reads that mapped uniquely to the genome without any mismatches.
Calculating read density—We calculated the normalized read density of a ChIP-seq or 
Chem-seq dataset in any region using the Bamliquidator (version 0.9) read density calculator 
(https://github.com/BradnerLab/pipeline/wiki/bamliquidator). Briefly, ChIP-Seq reads 
aligning to the region were extended by 200bp and the density of reads per basepair (bp) was 
calculated. The density of reads in each region was normalized to the total number of million 
mapped reads producing read density in units of reads per million mapped reads per bp 
(rpm/bp).
Identifying ChIP-seq and Chem-seq enriched regions—We used the MACS 
version 1.4.2 (Model based analysis of ChIP-Seq)34 peak finding algorithm to identify 
regions of ChIP-Seq enrichment over background. A p-value threshold of enrichment of 
1e-9 was used for all datasets. The GEO accession number and background used for each 
dataset can be found in the accompanying Supplementary Table 2.
Creating heatmap representations of ChIP-seq occupancy—Heatmaps of ChIP-
seq occupancy for various factors were created as described35. Heatmaps were created for 
the +/− 10kb region flanking all transcription start sites (TSS) or for the +/−10kb region 
flanking all TSS distal BET bromodomain bound enhancers. Each row plots a specific TSS 
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or enhancer region. Rows are ranked by peak occupancy of BET bromodomains as 
determined by Bio-JQ1 Chem-seq signal (Fig. 1d).
Correlating BRD4 and H3K27ac occupancy to Bio-JQ1—Occupancy of BRD4 and 
H3K27ac was correlated to Bio-JQ1 occupancy at all regions of Bio-JQ1 enrichment in 
SUM159 cells. Pearson correlation statistics are shown (Extended Data Fig. 3a). To quantify 
changes in BRD4 or H3K27ac occupancy upon JQ1 treatment, all Bio-JQ1 enriched regions 
were ranked in SUM159 cells and then binned (n=10). Corresponding boxplots of BRD4 or 
H3K27ac log2 fold change +/− JQ1 are shown for each bin (Extended Data Fig. 3b).
Mapping enhancers and super-enhancers using Bio-JQ1 occupancy or BRD4
—Enhancers and super enhancers (SEs) were mapped using the ROSE software package 
described12,13 and available at (younglab.wi.mit.edu/super_enhancer_code.html). In 
SUM159 and SUM159R cells, Bio-JQ1 Chem-Seq enriched regions were used to map 
enhancers and SEs (Fig. 1f). In SUM149 cells, BRD4 ChIP-seq enriched regions were used 
to map enhancers and SEs (Extended Data Fig. 3). Enhancers are defined as regions of Bio-
JQ1 binding not contained in promoters.
Quantifying changes in gene expression of SE proximal genes—Genes within 
50kb of SE in SUM159 or SUM149 were identified and filtered for expression status (> 1 
FPKM expression in any sample), and filtered to remove non poly-adenylated transcripts 
(e.g. microRNAs). For SUM159, log2 fold changes in gene expression at SE associated 
genes or all expressed genes was compared at 3, 12, and 24 hours post JQ1 treatment (Fig. 
1g). For SUM149, comparisons were made at 12 hours post JQ1 treatment (Extended Data 
Fig. 3f). The statistical significance of differences between distributions of changes was also 
assessed using a Welch's two-tailed t test.
Identifying differentially expressed genes upon JQ1 treatment—To identify 
genes differentially regulated by JQ1 treatment in SUM159 or SUM149 cells, all genes with 
a > log2 fold change in expression were ordered by fold change at 24 hours +/− JQ1 for 
SUM159 or at 12 hours +/− JQ1 for SUM149. The log2 row median normalized fold change 
for each gene is displayed as a heatmap in Extended Data Fig. 3g for SUM159 and in 
Extended Data Fig. 3h for SUM149. For subsequent gene set and pathway analysis, 
SUM159 genes with consistent and statistically significantly altered expression were 
selected using a Welch's two-tailed t test between DMSO and JQ1 treated expression values 
at 12 and 24 hours. A p-value cutoff of 0.01 was applied (Extended Data Fig. 3k).
Identifying gained/lost SE between SUM159 and SUM159R—SE differential 
regions were defined as in Brown et al. 201436. Briefly, in order to quantify changes in 
super-enhancers between two conditions, background subtracted ChIP-Seq signal was 
calculated at the set of all enhancer regions considered super in at least one condition. 
Gained/lost super-enhancers were determined as those with a greater than log2 fold change 
signal in either direction. The log2 fold change in Bio-JQ1 occupancy at all rank ordered SE 
containing regions is shown in Fig. 2c. SE regions were classified as either gained, 
conserved, or lost. Gained/lost regions were classified as those with > 1 log2 fold change in 
either direction. Conserved regions were classified as those with < 0.25 log2 fold change in 
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either direction. The log2 fold change in either BRD4 or proximal (within 50kb of region) 
gene expression is shown in Extended Data Fig. 5d-f.
Quantifying changes in BRD4 and H3K27ac occupancy upon JQ1 treatment in 
either SUM159 or SUM159R cells at Bio-JQ1 regions—Log2 fold changes in BRD4 
or H3K27ac were quantified at Bio-JQ1 enriched regions in their respective cell line and 
shown in Extended Data Fig. 5c.
Quantifying changes in BRD4 and H3K27ac as a function of Bio-JQ1 or BRD4 
occupancy—Bio-JQ1 enriched regions in SUM159 or BRD4 enriched regions in SUM149 
were ranked by increasing levels and then distributed into 10 bins. Log2 fold changes in 
BRD4 or H3K27ac were quantified in each bin of regions and displayed as a box plot 
(Extended Data Fig. 3b,c).
Quantifying changes in BRD4 occupancy upon JQ1 treatment in all TNBC—
Log2 fold changes in BRD4 upon JQ1 treatment were quantified at BRD4 enriched regions 
in each respective cell line Extended Data Fig. 6c.
All code related to genomic and transcriptome analysis can be found at https://github.com/
BradnerLab/TNBC
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Extended Data
Extended Data Figure 1. BET bromodomain proteins and cell growth in TNBCs
All error bars represent SD, n=3. a, Cellular viability of SUM159 and MDA-MB-231 cells 
expressing TET-inducible BRD4-targeting or lacZ shRNAs. P-values indicate statistical 
significance of the observed differences (paired t-test). b, Cellular viability four days after 
transfection of siRNAs targeting BET bromodomain proteins. *indicate statistical 
significance (paired t-test) of the marked differences as follows: SUM159: siBRD2 vs. 
siBRD3, p=0.002; siBRD3 vs. siBRD4, p=0.0006, MDA-MB-231: siBRD2 vs. siBRD3, 
p=0.006; siBRD2 vs. siBRD4, p=0.002; siBRD3 vs. siBRD4, p=0.016, MDA-MB-468: 
siBRD2 vs. siBRD3, p=0.0009; siBRD3 vs. siBRD4, p=0.0055, MDA-MB-436: siBRD2 vs. 
siBRD4, p=0.002; siBRD3 vs. siBRD4, p=0.015, ZR-75-1: siBRD2 vs. siBRD3, P=0.0169; 
siBRD3 vs. siBRD4, p=0.007. c, Immunoblot analysis of BET bromodomain proteins four 
days after siRNA transfection. d, Cell cycle profile of SUM159 cells synchronized in G2/M 
with 100ng/ml nocodazole followed by replating to fresh medium with DMSO or JQ1 
(500nM) added at -1h or at 3h after release. Cells were collected at different time points (0, 
6, 12h) after release. e, Immunoblot analysis of the indicated proteins at different time points 
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(0, 3, 6, 12h) after release of SUM159 cells synchronized with 100ng/ml nocodazole 
followed by replating to fresh medium with DMSO or JQ1 (500nM) added at 1hr before or 
3hrs after release. f, Cell cycle analysis of SUM159 cells following 72 hr treatment with JQ1 
(500nM) or downregulation of BRD4 using TET-inducible shRNAs. g, Annexin V staining 
of SUM159 cells following 72 hr treatment with JQ1 (500nM) downregulation of BRD4 
using TET-inducible shRNAs. All error bars represent SEM. h, Immunoblot analysis of the 
indicated proteins in a panel of breast cell lines; color scheme as in panel a. For gel source 
data, see Supplementary Figure 1.
Extended Data Figure 2. Response to BBIs in TNBCs
a, Immunoblot analysis of the indicated proteins at different time points following JQ1 
treatment (500nM) in SUM159 cells (top) and at different JQ1 doses for 24h treatment in 
SUM159 and MDA-MB-436 cells (bottom). b, Immunoblot analysis of the indicated 
proteins at different time points following JQ1 treatment (500nM) in SUM149, SUM159 and 
MDA-MB-231 cells. c, H&E staining of SUM159 cells after 3 days of JQ1 treatment. d, - 
Senescence β-galactosidase staining of SUM159 and MDA-MB-231 cells after 3 days of 
JQ1 treatment. Scale bars show 100μm. e, Box plots depict the weights of xenografts 30 
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days after injection of MDA-MB-231 (2×106) and IDC50X (2×105) cells into inguinal 
mammary fat pads of NOG mice; n indicates the number of mice/experiment. P-values 
indicate statistical significance of the observed differences (unpaired t-test). Error bars 
represent SEM. Mice were administered JQ1 (50mg/kg, daily) or vehicle only (control) for 
14 days beginning at day 16 (MDA-MB-231) or 10 (IDC50X) after injection (after tumors 
reached palpable size). For EL12-58X PDX, mice were implanted with pieces of tissue 
measuring 1×3×3mm into the inguinal mammary fat pads and were administered daily JQ1 
(50mg/kg) for 14 days beginning at day 21 after injection (after tumors reached palpable 
size). f, Bromodeoxyuridine (BrdU) and luminal low (Low MW CK) and basal high (High 
MW CK) molecular weight cytokeratin staining of EL12-58 xenograft with or without JQ1 
treatment. Scale bars show 50μm. g, Tumor volume of SUM159 cells expressing TET-
inducible BRD4-targeting shRNAs. Mice were administered doxycycline or vehicle only 
(control) for 39 days beginning at day 21 after injection (after tumors reached palpable size). 
Error bars represent SD, n=4 (shBRD4-1 experiment) and n=5 (shBRD4-2 experiment) h, 
Hematoxylin-eosine staining and immunofluorescence analysis of basal (basal cytokeratin, 
cytokeratin 17, pSTAT3, and CD44) and luminal (luminal cytokeratin, cytokeratin 18, and 
CD24) markers in SUM159 xenografts with or without JQ1 treatment. Scale bars show 
100μm for H&E and 50μm for immunofluorescence, respectively. For gel source data, see 
Supplementary Figure 1.
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Extended Data Figure 3. SUM149 JQ1 response
a, Scatter plots showing the relationship between the genomic binding of BRD4 and Bio-
JQ1 (left) or H3K27ac and Bio-JQ1 (right) at all Bio-JQ1 enriched bound regions. Units of 
genomic occupancy are in rpm/bp. A simple linear regression is drawn in black. Pearson 
correlation statistics are also shown. b, Boxplots showing the log2 fold change in BRD4 +/− 
JQ1 (left) or H3K27ac +/− JQ1 (right) at Bio-JQ1 bound regions in SUM159. The 12,999 
Bio-JQ1 regions are ranked by increasing Bio-JQ1 binding and divided into 10 separate bins 
(displayed from left to right). The statistical significance of the difference in the mean BRD4 
log2 fold change between the weakest and strongest Bio-JQ1 bound region bins is shown 
(Welch's t-test *** p-value < 1e-10). c, Boxplots showing the log2 fold change in BRD4 +/− 
JQ1 (left) or H3K27ac +/− JQ1 (right) at BRD4 bound regions in SUM149. The 5,696 
BRD4 bound regions are ranked by increasing background subtracted BRD4 binding and 
divided into 10 separate bins (displayed from left to right). The statistical significance of the 
difference in the mean BRD4 log2 fold change between the weakest and strongest BRD4 
bound region bins is shown (Welch's t-test *** p-value < 1e-10). d, Ranked plots of 
enhancers defined in untreated SUM149 cells ranked by increasing BRD4 signal (units 
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rpm). Enhancers are defined as regions of BRD4 binding not contained in promoters. The 
cutoff discriminating typical from super-enhancers is shown as a dashed gray line. 
Enhancers associated with TNBC characteristic genes are highlighted. e, Scatter plots 
showing the relationship between the log2 fold change in gene expression upon 12hr JQ1 
treatment in SUM149 (y-axis) and SUM159 (x-axis). A simple linear regression is drawn in 
red. The Pearson correlation statistic is also shown. f, Boxplots showing the log2 fold change 
in expression relative to DMSO control of either all active genes or super-enhancer (SE) 
associated upon 12hr JQ1 treatment. The statistical significance of the difference in 
expression change between all active genes and super-enhancer associated genes is shown 
by a Welch's t-test * p-value < 1e-3). g, Heatmap showing the expression of genes that are 
up or down regulated by JQ1 versus DMSO after 24 hours treatment. Each row shows the 
expression of a single gene in either DMSO or JQ1 treated cells at 3, 12, and 24 hours after 
treatment. Expression values are colored according to fold change relative to the median for 
each row. Genes are ordered by fold change +/− JQ1 24 hours after treatment. h, Heatmap 
showing the expression of genes that are up or down regulated by JQ1 versus DMSO after 
12 hours treatment in SUM149 and SUM149R cells. Each row shows the expression of a 
single gene in either DMSO or JQ1 treated cells at 12 hours after treatment. Expression 
values are colored according to fold change relative to the median for each row. Genes are 
ordered by fold change +/− JQ1 12 hours after treatment in SUM149 cells. i,j, Boxplots 
showing the log2 fold change in expression at genes that are up (i) or down (j) regulated by 
JQ1 versus DMSO after 12 hours of treatment in parental SUM149 cells. Log2 fold change 
in expression is shown for either parental SUM149 (left) or resistant SUM149R (right) cells. 
k, Top signaling pathways affected by JQ1-induced gene expression changes in SUM159 
cells. l, Viable cell numbers of SUM149 (left) and SUM149R (right) treated with different 
doses of JQ1 (2μM, 10μM). Error bars represent SD, n=3. P-values indicate statistical 
significance of the observed differences (two-way ANOVA with Bonferroni multiple 
comparison correction).
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Extended Data Figure 4. Characterization of SUM159R cells
a, Expression of ABC transporters in SUM159 and SUM159R cells. The expression of 29 
ABC transporters was analyzed based on RNA-seq data on the two cell lines. b, Assay for 
MDR (multi drug resistance) pumps in SUM159 and SUM159R cells treated with JQ1 alone 
or together with verapamil based on microscopic examination (left) and FACS (right) of 
cells labeled with fluorescent MDR substrate. c, Immunoprecipitation analysis of 
Biotinylated JQ1 (Bio-JQ1) in SUM159 and SUM159R cells with JQ1 treatment at different 
time points following immunoblot for the indicated proteins. d, Cellular viability of 
SUM159 and SUM159R cells treated with CXCR2 and JAK2 inhibitors. Error bars 
represent SD, n=3. e, Cellular viability of SUM159, and pool and single cell clones of 
SUM159R cells treated with different doses of JQ1. Error bars represent SD, n=3. f, Tumor 
weight of xenografts derived from SUM159 and SUM159R cells. Mice were administered 
JQ1 for 14 (SUM159) and 30 (SUM159R) days beginning at day 14 and 26, respectively, 
after injection. P-values indicate statistical significance of the observed differences (unpaired 
t-test). Error bars represent SEM. g, Immunoblot analysis of BCL-XL expression in 
SUM159 and SUM159R cells before and after JQ1 3h treatment (500nM). h, Dynamic BH3 
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profiling reveals inverse apoptotic response to JQ1 in SUM149R and SUM159R cells. In 
parental lines JQ1 increases priming relative to untreated cells indicating an increase in 
apoptotic propensity. In resistant lines JQ1 reduces priming indicating greater resistance to 
apoptosis relative to untreated cells. P-values indicate statistical significance of the observed 
differences (two-way ANOVA). Error bars represent SEM, n=5. For gel source data, see 
Supplementary Figure 1.
Extended Data Figure 5. BRD4 binding in SUM159R cells
a, Cellular viability of SUM159 and SUM159R cells transfected with siRNAs targeting 
bromodomain proteins. *indicate statistical significance (paired t-test) of the marked 
differences as follows: SUM159: siBRD2 vs. siBRD3, p=0.013, siBRD3 vs. siBRD4, 
p=0.0154 and SUM159R: siBRD2 vs. siBRD3, p=0.0159, siBRD2 vs. siBRD4, p=0.0048; 
siBRD3 vs. siBRD4, p=0.0068. b, Cellular viability of SUM159R cells expressing TET-
inducible BRD4-targeting or lacZ shRNAs. All error bars represent SEM. P-values indicate 
statistical significance of the observed differences (unpaired t-test). c, Boxplot showing the 
log2 fold change in H3K27ac genomic occupancy at regions bound by Bio-JQ1 in parental 
Shu et al. Page 22
Nature. Author manuscript; available in PMC 2016 July 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
SUM159 or resistant SUM159R cells. d, Heatmap showing the expression of genes that are 
up or down regulated by JQ1 versus DMSO after 24 hours treatment in parental SUM159 
cells. Each row shows the expression of a single gene in either DMSO or JQ1 treated cells at 
24 hours after treatment in SUM159 cells (left four columns) or SUM159R cells (right four 
columns). Expression values are colored according to fold change relative to the median for 
each row. Genes are ordered by fold change +/− JQ1 24 hours after treatment. e,f, Boxplots 
showing the log2 fold change in expression at genes that are up (e) or down (f) regulated by 
JQ1 versus DMSO after 24 hours of treatment in parental SUM159 cells. Log2 fold change 
in expression is shown for either parental SUM159 or resistant SUM159R cells. g, Boxplots 
showing expression of genes that are up or down regulated by JQ1 versus DMSO after 24 
hours of treatment in parental SUM159 cells. Expression is shown in DMSO and JQ1-
treated conditions in units of FPKM for either parental SUM159 (left) or resistant 
SUM159R (right) cells. The statistical significance of the difference between gene 
expression distributions for SUM159 DMSO and JQ1 treated cells is shown (p <0.01). The 
difference between all other distributions are considered non significant (N.S). The statistical 
significance of the difference between SUM159 DMSO gene expression distribution and all 
other distributions is shown (* p-value < 1e-3). The difference between all other 
distributions are considered non significant. h, Examples of luminal and basal cell-specific 
genes, and MYC in SUM159 and SUM159R cells. RNA-seq tracks are shown. i, H&E 
staining and immunofluorescence analysis of luminal (CK18 and LMW) and basal (CK17 
and HMW) cytokeratins and luminal (VIM and CD24) and basal (CDH1, CD44, and 
pSTAT3) cell markers in SUM159R xenografts. All error bars represent SEM. Scale bars 
show 100μm for H&E and 50μm for IF respectively.
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Extended Data Figure 6. JQ1 response in other breast cancer cell lines
a,b, Gene tracks depicting BRD4 + DMSO and BRD4 + JQ1 in multiple TNBC cells at the 
BCL-xL (a) or SOD2 (b) gene loci. The x-axis shows position along the chromosome with 
gene structures drawn below. The y-axis shows genomic occupancy in units of rpm/bp. The 
BCL-xL and SOD2 super-enhancers are shown as a red bar at the top. c, Box plots showing 
the log2 fold change in BRD4 occupancy +/− JQ1 for all BRD4 bound regions in each cell 
line for multiple TNBC. Cell lines are ordered by their JQ1 (IC50) and colored by their 
sensitivity. d, Gene tracks depicting H3K27AC occupancy at the BCL-xL locus in SUM149 
parental (top, light blue) or SUM149R resistant (bottom, dark blue) cells. The x-axis shows 
position along the chromosome with gene structures drawn below. The y-axis shows 
genomic occupancy in units of rpm/bp. All error bars represent SEM.
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Extended Data Figure 7. 
Word clouds depicting BRD4-associated proteins identified in RIME analysis.
Extended Data Figure 8. Mechanism of BBI-resistance
a, Immunoblot analysis of BRD4 immunoprecipitates for MED1 in the indicated cell lines 
with or without JQ1 treatment (5uM, 3h). b, Immunoblot analysis of long (BRD4L) and 
short (BRD4S) forms of BRD4 after transfection of siRNAs. c, Immunoblot analysis of the 
Shu et al. Page 25
Nature. Author manuscript; available in PMC 2016 July 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
indicated exogenously expressed FLAG-tagged BRD4 proteins in SUM159 and SUM159R 
cells. d, Immunoblot analysis of phospho-BRD4 (pBRD4) and BRD4 in SUM159 and 
SUM159R cells treated with the indicated doses of CK2, PI3K, and MEK inhibitors for 
2hrs. e, Immunoblot analysis of pBRD4, BRD4, MED1 and ACTB in the indicated cell lines 
with or without JQ1 treatment. f, Immunoblot analysis of CK2 substrates in SUM159 and 
SUM159R cells following CK2 inhibitor (CX-4945, 10μM) 3h treatment. g, Immunoblot 
analysis of pBRD4 and BRD4 in SUM149 cell line treated with different doses of the 
indicated PP2A inhibitors for 3hrs. ACTB was used as loading control. h, Immunoblot 
analysis of pBRD4 and BRD4 in the indicated cell lines treated with different doses of 
phenothiazine for 6hrs. i, Immunofluorescence analysis of exogenous FLAG-tagged BRD4 
proteins (WT, BD, 7D and 7A) in SUM159 cells with or without JQ1 treatment (5μM, 3hrs). 
Scale bars show 20μm. For gel source data, see Supplementary Figure 1.
Extended Data Figure 9. 
Phospho-BRD4 levels in xenografts and primary TNBC samples. a, Immunofluorescence 
analysis of phospho-BRD4 (pBRD4) in SUM159 parental and SUM159R xenografts 
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showing that resistance is associated with higher pBRD4 levels. b, Examples of pBRD4 
immunofluorescence in patient tumors depicting variability among different TNBC samples. 
Scale bars show 50μm. c. Mean intensity of phospho-BRD4 (pBRD4) in tissue samples from 
83 patients with early-stage triple negative breast cancer (TNBC). d, Examples of AR and 
basal cytokeratin (bCK, HMW CK) immunofluorescence in TNBC samples. Scale bars 
show 50μm. e, Box plot depicting pBRD4 signal intensity in TNBCs tumors with the 
indicated AR and bCK expression patterns. None of the differences among groups were 
significant (ANOVA test – p = 0.5413 and Dunnett's multiple comparisons test - not 
significant). f, Kaplan-Meier estimates of disease-free survival (DFS) and overall survival 
(OS) in TNBC subgroups using a median-split of pBRD4 intensity. Disease outcomes were 
evaluated in 83 of 89 TMA samples. Patients with low pBRD4 had a worse overall prognosis 
with a five-year RFS of 66.2% (95% CI 52.7-83.1%), compared to an RFS of 86.4% (95% 
CI 76.0-98.3%) among patients with high pBRD4 (HR=2.3, 95%CI 0.98-5.4, p=0.06). 
However, with this small sample size this difference did not reach statistical significance, 
nor did a ratiometric (2-fold) consideration of pBRD4 status and overall survival (HR=2.0, 
95%CI 0.67-5.9, p=0.22).
Extended Data Figure 10. 
Overcoming BBI-resistance. a-c, Synergy studies of JQ1 with ABT737 (BCL-xl and BCL-2 
inhibitor) (a), CX-4945 (CK2 inhibitor) (b) and Perphenazine (PP2A activator) (c). Points 
represent paired values of drug concentrations assessed for synergism. The diagonal line 
signifies drug additivity. Points above the line represent antagonistic drug combinations, and 
those below the line represent synergistic drug combinations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Response to BBIs in breast cancer
a, Heatmap of mean IC50s of BBIs and inactive analogues in breast cell lines. Error bars 
represent SEM. b, Immunofluorescence of basal (basCK) and luminal (lumCK and CK18) 
cytokeratins in TNBC lines. Scale bars 20μm. c, Box plots depicting xenograft weights; n 
indicates the number of mice/experiment. d, Heatmap showing biotinylated JQ1 (Bio-JQ1), 
BRD4, and H3K27ac binding at transcription start site (TSS) and Bio-JQ1-bound enhancer 
regions. Each row represents a single genomic region (+/− 10kb) from TSS or enhancer 
center. Genomic occupancy is shaded by binding intensity in units of reads per million per 
base pair (rpm/bp). e, Gene tracks depicting Bio-JQ1 and BRD4 −/+ JQ1 in SUM159 cells 
at the HIF1A locus. x-axis: chromosome position with gene structures below, y-axis: 
genomic occupancy in units of rpm/bp, red bar: HIF1A super-enhancer. f, Plot of enhancers 
defined in untreated SUM159 cells ranked by increasing Bio-JQ1 signal (units rpm). Gray 
line marks cutoff discriminating typical from super-enhancers. g, Boxplots showing the log2 
fold change in expression relative to control of either all active or super-enhancer (SE) 
associated genes upon JQ1 treatment.
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Figure 2. Acquired BBI-resistance in TNBC
All error bars represent SD, n=3. a, Viable cell numbers after JQ1 treatment. b, Cellular 
viability after treatment with BBIs. c, Genomic regions containing a super-enhancer in 
SUM159 or SUM159R cells ranked by log2 change in Bio-JQ1 genomic binding signal. X-
axis: log2 fold change in Bio-JQ1 signal colored by intensity of change. d, e, Boxplot 
showing the log2 fold change in BRD4 genomic occupancy (d) and gene expression (e) at 
regions with gained, conserved, or lost Bio-JQ1 binding in SUM159R vs.. SUM159 cells. 
f,g, Gene tracks depicting Bio-JQ1, BRD4, and H3K27ac at the BCL-xL (f) and SOD2 (g) 
locus. The x-axis shows position along the chromosome with gene structures drawn below. 
The y-axis shows genomic occupancy in units of rpm/bp. h, Boxplot showing the log2 fold 
change in BRD4 genomic occupancy at regions bound by Bio-JQ1.
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Figure 3. Mechanism of BBI-resistance in TNBCs
All error bars represent SD, n=3. a, Plot depicting changes in BRD4-associated proteins in 
SUM159 and SUM159R cells following JQ1 treatment based on SILAC RIME. The axes 
represent log10 of fold change (FC). b, Immunoblot analysis of BRD4 immunoprecipitates 
and total cell lysates in SUM159 and SUM159R cells. For gel source data, see 
Supplementary Figure 1. c, Cellular viability of SUM159 and SUM159R cells expressing 
exogenous WT, BDmut, 7A and 7D mutant BRD4 with concomitant knock-down of 
endogenous BRD4. d, e, Sensitivity of SUM159 (d) and SUM159R (e) cells expressing 
exogenous WT or BDmut BRD4 to JQ1 with concomitant knock-down of endogenous 
BRD4.
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Figure 4. Regulation and relevance of BRD4 phosphorylation
All error bars represent SD, n=3. a, Immunoblot for the indicated proteins following JQ1 
treatment. b, Immunoblot for the indicated proteins after knock-down of PP2A A or C or 
both subunits. c, Viable cell numbers of JQ1-treated control and shPP2A-C expressing 
SUM149 cells. d, Immunoblot of pBRD4 and BRD4 in SUM159R cells following 
phenothiazine (PTZ) treatment. e, Viable cell numbers of SUM159R cells treated with JQ1, 
phenothiazine or both compounds. f,g Immunoblot of BRD4 immunoprecipitates and total 
cell lysates of SUM159R cells after 3hrs treatment with JQ1 and CK2i (f) and JQ1 and PTZ 
(g). h, Immunoblot of FLAG-BRD4 (WT or mutant) immunoprecipitates and total cell 
lysates after 3hrs treatment with JQ1. i, JQ1 sensitivity of SUM159 and SUM159R cells 
expressing exogenous WT or mutant (7A, 7D) BRD4. For gel source data, see 
Supplementary Figure 1.
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